Metalloproteinase inhibitors and the prevention of connective tissue breakdown

https://doi.org/10.1016/0163-7258(96)00015-0Get rights and content

Abstract

The primary agents responsible for cartilage and bone destruction in joint diseases are active proteinases degrading collagen and proteoglycan. All four main classes of proteolytic enzymes are involved in either the normal turnover of connective tissue or its pathological destruction. These proteinases are made by different cells found within the joints. Both extracellular and intracellular pathways exist, and individual enzymes can be inhibited by specific proteinaceous inhibitors that block their activity. Recent research has implicated the matrix metalloproteinases in many of the processes involved in joint diseases. Conventional treatments do little to affect the underlying disease processes, and recently, the use of proteinase inhibitors has been suggested as a new therapeutic approach. A large variety of different synthetic approaches have been used and highly effective metalloproteinase inhibitors have been designed, synthesised and tested. These metalloproteinase inhibitors can prevent the destruction of animal cartilage in model systems and slow the progression of human tumours. Future patient trials will test the effectiveness of these compounds in vivo for the treatment of joint diseases.

References (245)

  • L.A. Cornelius et al.

    Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration

    J. Invest. Dermatol.

    (1995)
  • K. Darlak et al.

    Thiol-based inhibitors of mammalian collagenase. Substituted amide and peptide derivatives of the leucine analogue, 2-[(R,S)-mercaptomethyl]-4-methylpentanoic acid

    J. Biol. Chem.

    (1990)
  • Y.A. DeClerck et al.

    Protease inhibitors: role and potential therapeutic use in human cancer

    Eur. J. Cancer (A)

    (1994)
  • D.T. Denhardt et al.

    Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions

    Pharmacol. Ther.

    (1993)
  • P. Devarajan et al.

    Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells

    J. Biol. Chem.

    (1992)
  • A.J.P. Docherty et al.

    The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases

    Trends Biotechnol.

    (1992)
  • A.J. Ellis et al.

    The prevention of collagen brekadown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor

    Biochem. Biophys. Res. Comm.

    (1994)
  • G.B. Fields et al.

    Sequence specificity of human synovial fibroblast collagenase

    J. Biol. Chem.

    (1987)
  • J.M.P. Freije et al.

    Molecular cloning and expression of collagenase-3, a novel human matrixmetalloproteinase produced by breast carcinomas

    J. Biol. Chem.

    (1994)
  • S.J. Gadher et al.

    Degradation of cartilage collagens type II, IX, X and XI by enzymes derived from human articular chondrocytes

    Matrix

    (1990)
  • J. Gavrilovic et al.

    The role of plasminogen in cell-mediated collagen degradation

    Cell Biol. Int. Rep.

    (1989)
  • G.I. Goldberg et al.

    Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin

    J. Biol. Chem.

    (1992)
  • K.A. Hasty et al.

    Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases

    J. Biol. Chem.

    (1990)
  • H.J. Andrews et al.

    Transforming growth factor-beta causes partial inhibition of interleukin-1-stimulated cartilage degradation in vitro

    Biochem. Biophys. Res. Commun.

    (1989)
  • H.J. Andrews et al.

    Inhibition of interleukin-1-induced collagenase production in human articular chondrocytes in vitro by recombinant human inteferongamma

    Arthritis Rheum.

    (1990)
  • H.J. Andrews et al.

    Modulation of plasminogen activator production by interleukin 1: differential responses of fibroblasts derived from human skin and rheumatoid and non-rheumatoid synovium

    Biochim. Biophys. Acta

    (1990)
  • H.J. Andrews et al.

    A synthetic peptide metalloproteinase inhibitor but not TIMP prevents the breakdown of proteoglycan within articular cartilage in vitro

    Agents Actions

    (1992)
  • A.J. Barrett

    Introduction to the history and classification of proteinases

  • A.J. Barrett et al.

    The interaction of α2M with other proteases

    Biochem. J.

    (1973)
  • P. Basset et al.

    Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review

    Breast Cancer Res. Treat.

    (1993)
  • H. Birkedal-Hansen et al.

    Matrix metalloproteinases: a review

    Crit. Rev. Oral. Biol. Med.

    (1993)
  • T.L. Blundell

    Metalloproteinase super-families and drug design

    Nature Struct. Biol.

    (1994)
  • W. Bode et al.

    The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity

    EMBO J.

    (1994)
  • R. Borkakoti et al.

    Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor

    Nature Struct. Biol.

    (1994)
  • J.J.W. Breckton et al.

    Matrix metalloproteinases and TIMP-1 localization at sites of osteogenesis in the craniofacial region of the rabbit embryo

    Anat. Rec.

    (1995)
  • F. Bredveld et al.

    Minocycline treatment for rheumatoid arthritis: an open dose finding study

    J. Rheumatol.

    (1990)
  • C.E. Brinckerhoff

    Joint destruction in arthritis: metalloproteinases in the spotlight

    Arthritis Rheum.

    (1991)
  • C.E. Brinckerhoff et al.

    Regulation of collagenase gene expression in synovial fibroblasts

    Ann. NY Acad. Sci.

    (1990)
  • P.D. Brown

    Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer

    Ann. NY Acad. Sci.

    (1994)
  • M.F. Browner et al.

    Matrilysin—Inhibitor complexes: common themes among metalloproteases

    Biochemistry

    (1995)
  • D.F. Busiek et al.

    Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones

    J. Immunol.

    (1995)
  • T.A. Butler et al.

    Inhibition of ovulation in the perfused rat ovary by the synthetic collagenase inhibitor SC 44463

    Biol. Reprod.

    (1991)
  • D.J. Buttle et al.

    Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases; evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation

    Arthritis Rheum.

    (1993)
  • D.J. Buttle et al.

    Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

    Clin. Pathol.: Mol. Pathol.

    (1995)
  • I.K. Campbell et al.

    Effects of tumour necrosis factor on resorption of human articular cartilage and production of plasminogen activators by human articular chondrocytes

    Arthritis Rheum.

    (1990)
  • E. Canalis et al.

    Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures

    Endocrinology

    (1995)
  • C.B. Caputo et al.

    Effect of synthetic metalloprotease inhibitors on cartilage autolysis in vitro

    J. Pharmacol. Exp. Ther.

    (1987)
  • J.P. Case et al.

    Stromelysin expression in rheumatoid synovium

    Am. J. Pathol.

    (1989)
  • J.P. Case et al.

    Stromelysin expression in the synovium of rats with experimental erosive arthritis

    J. Clin. Invest.

    (1989)
  • T.E. Cawston

    Metalloproteinases and connective tissue breakdown

    Rheumatol. Rev.

    (1994)

    • Cited by (245)

    • Developing efficient protocols for synthesis, antiosteoarthritic, antiinflammatory assessments and docking studies of nitrogen-containing bisphosphonate derivatives

      2017, Arabian Journal of Chemistry

    • Altered Gene and Protein Expressions in Torn Rotator Cuff Tendon Tissues in Diabetic Patients

      2017, Arthroscopy - Journal of Arthroscopic and Related Surgery

    • Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFβ1/smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis

      2014, Biochimie
      Citation Excerpt :

      The actions of MMPs are attenuated by specific inhibitors known as tissue inhibitors of matrix metalloproteinases (TIMP). TIMPs may act in the tissue environment to neutralize used Proteinases thereby preventing excessive and unwanted degradation away from the sites of metalloproteinase production [43]. Moreover, fibroblasts from patients with IPF express elevated levels of all TIMPs.

    • Matrix Metallopeptidase-1/Interstitial Collagenase

      2013, Handbook of Proteolytic Enzymes

    • Immunohistochemical expression of matrix metalloproteinases in the rabbit corneal epithelium upon UVA and UVB irradiation

      2012, Acta Histochemica

    • Challenges and opportunities of medicines for treating tendon inflammation and fibrosis: A comprehensive and mechanistic review

      2024, Fundamental and Clinical Pharmacology
    View all citing articles on Scopus
    View full text
    Copyright © 1996 Published by Elsevier Inc.